The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1713
In Brief: New Warning for Fezolinetant (Veozah)
Download PDF:   US English
Med Lett Drugs Ther. 2024 Oct 14;66(1713):168   doi:10.58347/tml.2024.1713e
Disclosures
Objective(s)
 Select a term to see related articles  drug safety   fezolinetant   menopause   Veozah 

The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity.1,2 The label of fezolinetant, which was approved by the FDA in 2023 for treatment of moderate to severe vasomotor symptoms due to menopause, already contained a warning about hepatic transaminase elevations associated with use of the drug.

The new warning was based on a single post-marketing case of acute mixed hepatocellular cholestatic drug-induced liver injury. The patient presented with fatigue, nausea, itching, jaundice, light-colored stools, dark urine, and elevated hepatic enzyme and total bilirubin levels within 40 days of starting fezolinetant.

Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels should be checked before starting fezolinetant, monthly for the first 3 months, and at 6 and 9 months after starting the drug. Fezolinetant should not be started if ALT or AST concentrations are ≥2 times the upper limit of normal (ULN) or if total bilirubin is elevated. The drug should be stopped if transaminase levels are >5 times the ULN or if transaminase levels are >3 times the ULN and total bilirubin level is >2 times the ULN.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article